Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with alzheimer's disease

Journal of Alzheimer's Disease

Volumn 40, Issue 3, 2014, Pages 595-603

  O'Caoimh, Rónán ^a   Healy, Liam ^a   Gao, Yang ^a   Svendrovski, Anton ^b   Kerins, David M ^c,d   Eustace, Joseph ^d   Kehoe, Patrick Gavin ^e   Guyatt, Gordon ^b   Molloy, D William ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d MERCY UNIVERSITY HOSPITAL   (Ireland)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

ACE inhibitors; Alzheimer's disease; cognitive; dementia; function; psychological decline

Indexed keywords

DOXYCYCLINE; FOSINOPRIL; LISINOPRIL; PERINDOPRIL; RAMIPRIL; RIFAMPICIN; TRANDOLAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD PRESSURE; CANADA; CAREGIVER; CLINICAL DEMENTIA RATING; COGNITION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; EDUCATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; COGNITION DISORDERS; COMPLICATION; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PSYCHOLOGICAL RATING SCALE; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DOXYCYCLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RIFAMPIN;

EID: 84901930177     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131694     Document Type: Article

References (84)

1. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64, 277-281.
2. Joas E, Backman K, Gustafson D, Ostling S, Waern M, Guo X, Skoog I (2012) Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension 59, 796-801.
3. Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, Preti P (2003) Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens 17, 781-785. (Pubitemid 37441435)
4. Fogari R, Mugellini A, Zoppi A, Marasi G, Pasotti C, Poletti L, Rinaldi A, Preti P (2004) Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 59, 863-868. (Pubitemid 38333676)
5. Kehoe PG, Passmore PA(2012) The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis 30, 251-268.
6. Fournier A, Oprisiu-Fournier R, Serot JM, Godefroy O, Achard JM, Faure S, Mazouz H, Temmar M, Albu A, Bordet R, Hanon O, Gueyffier F, Wang J, Black S, Sato N (2009) Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACEinhibitors. Expert Rev Neurother 9, 1413-1431.
7. Goodison WV, Frisardi V, Kehoe PG (2012) Calcium channel blockers and Alzheimer's disease: potential relevance in treatment strategies of metabolic syndrome. J Alzheimers Dis 30, 269-282.
8. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS,Welsh-Bohmer KA, Breitner JC (2006) Antihypertensive medication use and incident Alzheimer disease: The Cache County Study. Arch Neurol 63, 686-692.
9. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM (2011) Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 26, 699-708.
10. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340, b5465.
11. Ohrui T, Matsui T, Yamaya M, Arai H, Ebihara S, Maruyama M, Sasaki H (2004) Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 52, 649-650. (Pubitemid 38480653)
12. Staessen JA, Thijs L, Richart T, Odili AN, Birkenhager WH (2011) Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 57, e6-e7.
13. Poon IO (2008) Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy 28, 366-375. (Pubitemid 351328909)
14. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Goff DC Jr (2009) Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 169, 1195-1202.
15. Kehoe PG, Davies NM, Martin RM, Ben-Shlomo Y (2013) Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. J Alzheimers Dis 33, 999-1008.
16. Kehoe P, Miners S, Love S (2009) Angiotensins in Alzheimer's disease-friend or foe? Trends Neurosci 32, 619- 628.
17. Hajjar I, Hart M, Milberg W, Novak V, Lipstz L (2009) The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: Role of the renin angiotensin system inhibition. BMC Geriatr 9, 48.
18. Hajjar I, Hart M, ChenY, MackW, MilbergW, Chui H, Lipsitz L (2012) Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: A Double-Blind Randomized Clinical Trial. Arch Intern Med 172, 442-444.
19. Solfrizzi V, Scafato E, Frisardi V, Seripa D, Logroscino G, Kehoe PG, Imbimbo BP, Baldereschi M, Crepaldi G, Di Carlo A, Galluzzo L, Gandin C, Inzitari D, Maggi S, Pilotto A, Panza F; Italian. Longitudinal Study on AgingWorking Group (2013) Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age (Dordr) 35, 441-453.
20. Rozzini L, Chilovi BV, Bertoletti E, Conti M, Del Rio I, Trabucchi M, PadovaniA(2006) Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry 21, 550-555. (Pubitemid 44043756)
21. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H, Sasaki H (2004) Effects of brainpenetratingACEinhibitors on Alzheimer disease progression. Neurology 63, 1324-1325. (Pubitemid 39350046)
22. Gao Y, O'Caoimh R, Healy L, Kerins D, Guyatt G, Eustace J, Sammon D, Molloy DW (2013) Effects of centrally acting angiotensin converting enzyme inhibitors on the rate of cognitive decline in dementia. BMJ Open 3, e002881.
23. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 110, 1129-1134.
24. Kehoe PG, Russ C, McIlory S, Williams H, Holmans P, Holmes C, Liolitsa D, Vahidassr D, Powell J, McGleenon B, Liddell M, Plomin R, Dynan K, Williams N, Neal J, Cairns NJ, Wilcock G, Passmore P, Lovestone S, Williams J, Owen MJ (1999) Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 21, 71-72. (Pubitemid 29036286)
25. Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince van Duijn CM, Kehoe PG (2005) Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease.AmJ Epidemiol 162, 305-317. (Pubitemid 41389712)
26. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86, 1343- 1346. (Pubitemid 20370444)
27. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F (1992) Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51, 197-205.
28. Hemming ML, Selkoe DJ (2005) Amyloid beta -protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 280, 37644- 37650. (Pubitemid 41642372)
29. Hu J, Igarashi A, Kamata M, Nakagawa H (2001) Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 276, 47863-47868.
30. Oba R, Igarashi A, Kamata M, Nagata K, Takano S, Nakagawa H (2005) The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci 21, 733-740. (Pubitemid 40363508)
31. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S,Kehoe PG (2008) Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 34, 181-193. (Pubitemid 351327960)
32. Miners S, Ashby E, Baig S, Harrison R, Tayler H, Speedy E, Prince JA, Love S, Kehoe PG (2009) Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res 1, 163-177.
33. Miners JS, van Helmond Z, Raiker M, Love S, Kehoe PG (2010) ACE variants and association with brain Abeta levels in Alzheimer's disease. Am J Transl Res 3, 73-80.
34. Belbin O, Brown K, Shi H, Medway C, Abraham R, Passmore P, Mann D, Smith AD, Holmes C, McGuiness B, Craig D, Warden D, Heun R,K?olsch H, Love S, Kalsheker N,Williams J,OwenMJ, CarrasquilloM,Younkin S,Morgan K,KehoePG (2011) A multi-center study of ACE and the risk of late-onset Alzheimer's disease. J Alzheimers Dis 24, 587-597.
35. Tian M, Zhu D, Xie W, Shi J (2012) Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett 586, 3737-7345.
36. Zhu D, Shi J, Zhang Y, Wang B, Liu W, Chen Z, Tong Q (2011) Central angiotensin II stimulation promotes amyloid production in Sprague Dawley rats. PLoS One 6, e16037.
37. Yamada K, Uchida S, Takahashi S, Takayama M, Nagata Y, Suzuki N, Shirakura S, Kanda T (2010) Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res 1352, 176-186.
38. Yamada K, Horita T, Takayama M, Takahashi S, Takaba K, Nagata Y, Suzuki N, Kanda T (2011) Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Res 1421, 110-120.
39. Dong YF, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, Sueta D, Koibuchi N, Yamamoto E, Ogawa H, Kim-Mitsuyama S (2011) Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J 25, 2911-2920.
40. Tota S, Nath C, Najmi AK, Shukla R, Hanif K (2012) Inhibition of central angiotensin converting enzyme ameliorates scopolamine induced memory impairment in mice: Role of cholinergic neurotransmission, cerebral blood flow and brain energy metabolism. Behav Brain Res 232, 66-76.
41. Ferrington L, Palmer LE, Love S, Horsburgh KJ, Kelly PA, Kehoe PG (2012) Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse. Am J Transl Res 4, 151-164.
42. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H, ONTARGET/ TRANSCEND Investigators (2004) Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Patients with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am Heart J 148, 52-61. (Pubitemid 38906646)
43. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A, SCOPE Study Group (2003) The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21, 875-886. (Pubitemid 36677151)
44. Wharton W, Stein JH, Korcarz C, Sachs J, Olson SR, Zetterberg H, Dowling M, Ye S, Gleason CE, Underbakke G, Jacobson LE, Johnson SC, Sager MA, Asthana S, Carlsson CM (2012) The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis 32, 147-156.
45. Rosenberg P,MielkeM, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, Green RC, Welsh-Bohmer KA, Breitner JCS, Munger R, Lyketsos CG (2008) Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatric Psychiatry 16, 883-892.
46. Sumukadas D, Witham MD, Struthers AD, McMurdo MET (2007) Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ 177, 867-874. (Pubitemid 47612819)
47. Wong AKW, Lord SR, Sturnieks DL, Delbaere K, Trollor JN, Close JCT (2013) Angiotensin system-blocking medications are associated with fewer falls over 12 months in communitydwelling older people. J Am Geriatr Soc 61, 776-781.
48. Regan C, Katona C, Walker Z, Hooper J, Donovan J, Livingston G (2006) Relationship of vascular risk to the progression of Alzheimer disease. Neurology 67, 1357-1362. (Pubitemid 44632057)
49. Seripa D, Paroni G, MateraMG,Gravina C, Scarcelli C, Corritore M, D'Ambrosio LP, Urbano M, D'Onofrio G, Copetti M, Kehoe PG, Panza F, Pilotto A (2011) Angiotensin-converting enzyme (ACE) genotypes and disability in hospitalized older patients. Age (Dordr) 33, 409-419.
50. Kritchevsky SB, Nicklas BJ, Visser M, Simonsick EM, Newman AB, Harris TB, Lange EM, Penninx BW, Goodpaster BH, Satterfield S, Colbert LH, Rubin SM, Pahor M (2005) Angiotensin-converting enzyme insertion/deletion genotype, exercise, and physical decline. JAMA 294, 691-698. (Pubitemid 41159288)
51. Gard PR (2004) Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets 8, 7-14. (Pubitemid 38240020)
52. Braszko JJ, Karwowska-Polecka W, Halicka D, Gard PR (2003) Captopril and enalapril improve cognition and depressed mood in hypertensive patients. J Basic Clin Physiol Pharmacol 14, 323-343. (Pubitemid 38679252)
53. Deary IJ, Capewell S, Hajducka C, Muir AL (1991) The effects of captopril vs atenolol on memory, information processing and mood: a double-blind crossover study. Br J Clin Pharmacol 32, 347-353.
54. Rogers D, Pies R (2008) General medical drugs associated with depression. Psychiatry (Edgmont) 5, 28.
55. Molloy DW, Standish TI, Zhou Q, Guyatt G (2013) A multi-centre, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial. Int J Geriatr Psychiatry 28, 463-470.
56. Standish TI, Molloy DW, B'edard M, Layne EC, Murray EA, Strang D (1996) Improved reliability of the Standardized Alzheimer's Disease Assessment Scale (SADAS) compared with the Alzheimer's Disease Assessment Scale (ADAS). J Am Geriatr Soc 44, 712-716. (Pubitemid 26174392)
57. Schafer KA, Tractenberg RE, Sano M, Mackell JA, Thomas RG, Gamst A, Thal LJ, Morris JC, Alzheimer's Disease Cooperative, Study (2004) Reliability of monitoring the Clinical Dementia Rating in multicenter clinical trials. Alzheimer Dis Assoc Disord 18, 219-222. (Pubitemid 40076152)
58. Molloy DW, Alemayehu E, Roberts RS (1991) Reliability of a standardized mini-mental state examination compared with the traditional mini-mental state examination. Am J Psychiatry 148, 102-105.
59. MolloyDW, Standish TIM (1997)Aguide to the standardized mini-mental state examination. Int Psychogeriatrics 9, 87-94.
60. O'Caoimh R, Gao Y, McGlade C, Healy L, Gallagher P, Timmons S, Molloy DW (2012) Comparison of the quick mild cognitive impairment (Qmci) screen and the SMMSE in screening for mild cognitive impairment. Age Ageing 41, 624-629.
61. O'Caoimh R, Gao Y, Gallagher P, Eustace J, McGlade C, Molloy DW (2013) Which part of the quick mild cognitive impairment screen (Qmci) discriminates between normal cognition, mild cognitive impairment and dementia? Age Ageing 42, 324-330.
62. O'Caoimh R, Svendrovski A, Johnston B, Gao Y, McGlade C, Timmons S, Eustace J, Guyatt G, Molloy DW (2014) The quick mild cognitive impairment screen correlated with the standardised Alzheimer's disease assessment scale-cognitive section in clinical trials. J Clin Epidemiol 67, 87-92.
63. Yesavage JA (1988) Geriatric depression scale. Psychopharmacol Bull 24, 709-711.
64. Alexopoulos GA, Abrams RC, Young RC, Shamoian CA (1988) Cornell scale for depression in dementia. Biol Psych 23, 271-284. (Pubitemid 18047596)
65. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9, 179-186.
66. Molloy DW, McIlroy WE, Guyatt GH, Lever JA (1991) Validity and reliability of the dysfunctional behavior rating instrument. Acta Psychiatr Scand 84, 103-106.
67. Molloy DW, B'edard M, Guyatt GH, Lever JA (1996) Dysfunctional behaviour rating instrument. Int Psychogeriatr 8, 333-341.
68. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
69. Weyer G, Erzigkeit H, Kanowski S, Ihl R, Hadler D (1997) Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial. Int Psychogeriatrics 9, 123-138. (Pubitemid 27455497)
70. Marc LG, Raue PJ, Bruce ML (2008) Screening performance of the geriatric depression scale (GDS-15) in a diverse elderly home care population. Am J Geriatr Psychiatry 16, 914-921.
71. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
72. Hanes DS, Weir MR (2007) Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly. Am J Geriatr Cardiol 16, 175-182.
73. Henriksen EJ, Jacob S (2003) Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 196, 171-179. (Pubitemid 36676455)
74. Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, Carter C, Di Bari M, Guralnik JM, Pahor M (2002) Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 359, 926-930. (Pubitemid 34246382)
75. Montgomery H, Clarkson P, Barnard M, Bell J, Brynes A, Dollery C, Hajnal J, Hemingway H, Mercer D, Jarman P, Marshall R, Prasad K, Rayson M, Saeed N, Talmud P, Thomas L, Jubb M, World M, Humphries S (1999) Angiotensinconverting- enzyme gene insertion/deletion polymorphism and response to physical training. Lancet 353, 541-545. (Pubitemid 29078424)
76. Tollefson GD (1990) Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 27, 1133- 1142. (Pubitemid 20150025)
77. Kennelly S, Abdullah L, Kenny RA, Mathura V, Luis CA, Mouzon B, Crawford F, Mullan M, Lawlor B (2012) Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients - an open label trial. Int J Geriatr Psychiatry 27, 415-422.
78. Cesari M, Pedone C, Incalzi RA, PahorM(2010) ACE inhibition and physical function. results from the trial of angiotensin converting enzyme inhibition and novel cardiovascular risk factors (TRAIN) study. J Am Med Dir Assoc 11, 26.
79. Hutcheon SD, Gillespie ND, Crombie IK, Struthers AD, McMurdo ME (2002) Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart 88, 373-377.
80. Zi M, Carmichael N, Lye M (2003) The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther 17, 133-139. (Pubitemid 37174687)
81. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27, 2338-2345. (Pubitemid 44453578)
82. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS (2005) Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 165, 1147-1152. (Pubitemid 40720739)
83. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ (2001) Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 23, 1999-2010. (Pubitemid 34073191)
84. Sheehan B (2012) Assessment scales in dementia. Ther Adv Neurol Disord 5, 349-358.